The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

Continued to advance three clinical programs in immune-mediated diseases: The Phase 3 ONWARD program for ESK-001 in moderate-to-severe plaque psoriasis consists of two parallel 24-week global Phase 3 ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

Frailty and functional dependency affect treatment satisfaction and may require tailored care for older adults with psoriasis ...

New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions ...

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

Medically reviewed by Casey Gallagher, MD Psoriasis of the hands and feet, known as palmoplantar psoriasis, is an inflammatory autoimmune disorder that causes scaly, itchy skin patches on the palms ...